1
Clinical Trials associated with Recombinant fowlpoxvirus expressing HIV gag-pol antigens vaccine(Virax Pty)An Extension Study to Protocol VIR-NCHR-01 to Assess the Antiretrovirological Properties of a Therapeutic HIV Vaccine Candidate Based on Recombinant Fowlpox Virus (rFPV) (ITV Extension Study)
The objective of this phase I/II therapeutic human immunodeficiency virus (HIV) vaccine candidate study is to provide proof of concept for a HIV antigen delivery system in terms of safety, virological effects and selected immune responses in HIV infected individuals after cessation of antiretroviral combination therapy (ART).
100 Clinical Results associated with Recombinant fowlpoxvirus expressing HIV gag-pol antigens vaccine(Virax Pty)
100 Translational Medicine associated with Recombinant fowlpoxvirus expressing HIV gag-pol antigens vaccine(Virax Pty)
100 Patents (Medical) associated with Recombinant fowlpoxvirus expressing HIV gag-pol antigens vaccine(Virax Pty)
100 Deals associated with Recombinant fowlpoxvirus expressing HIV gag-pol antigens vaccine(Virax Pty)